Monoclonal antibody which aids investigation into T-cell related diseases.
| Inventor | Institute |
|---|---|
| Mike Owen | Cancer Research UK, Lincoln's Inn Fields Institute |
| Cat. #: | 151289 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology;Immunology |
| Application: | WB ; FACS ; IHC ; IF ; IP |
| Target: | TCR CBeta1 |
| Reactivity: | Human |
| Clone: | JOVI.1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Viney et al. 1993. Hybridoma. 11(6):701-13. PMID: 1284120. |
| Product description: | Monoclonal antibody specific for the variable region of T cell receptors in humans. This antibody aids the study of T-cell mediated diseases. Anti-TCR CBeta1 [JOVI.1] mAb recognises an epitope on the majority of TCRs. Anti-TCR CBeta1 [JOVI.1] mAb is capable of inducing proliferation of peripheral blood T cells. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Immunogen: | Human HA1.7 TCR beta chain expressed on transgenic mouse cells. |
| Immunogen Uniprot ID: | P01850 |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | The T cell receptor is expressed on all mature T cells. The T cell receptor is heterodimer of alpha/beta or gamma/delta chains, expressed on all mature T cells. TCR's recognize antigen peptides bound to MHC molecules, providing the basis of antigen specific response by T cells. Genetic mutations involving the T cell receptor beta locus have been associated with T cell lymphomas. JOVI.1 can be used for studies of T-cell mediated diseases, including autoimmunity and allergy. Antibody JOVI.1 recognised a determinant on the majority of TCRs, staining 50-75% of peripheral blood T cells and T cell lines expressing different V beta regions. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Rossatti et al. 2019. Cells. 8(11):1-13. PMID: 31690048. Beck et al. 2018. Hum Vaccin Immunother. 14(12):2864-2873. PMID: 30111232. Tesio et al. 2018. Hemasphere. 2(2):e38. PMID: 31723766. Risueño et al. 2008. PLoS ONE. 3(3):e1747. PMID: 18320063. Chen et al. 2007. J Biol Chem. 282(48):35361-72. PMID: 17897956. Gil et al. 2002. Cell. 109(7):901-12. PMID: 12110186. Viney et al. 1993. Hybridoma. 11(6):701-13. PMID: 1284120. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.